{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:59:59Z","timestamp":1791295199392,"version":"4.1.0"},"reference-count":29,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2016,5,6]],"date-time":"2016-05-06T00:00:00Z","timestamp":1462492800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Integr Cancer Ther"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>Hypothesis. Prior studies on patients with early B-cell lymphoid malignancies suggest that early intervention with curcumin may lead to delay in progressive disease and prolonged survival. These patients are characterized by increased susceptibility to infections. Rice bran arabinoxylan (Ribraxx) has been shown to have immunostimulatory, anti-inflammatory, and proapoptotic effects. We postulated that addition of Ribraxx to curcumin therapy may be of benefit. Study design. Monoclonal gammopathy of undetermined significance (MGUS)\/smoldering multiple myeloma (SMM) or stage 0\/1 chronic lymphocytic leukemia (CLL) patients who had been on oral curcumin therapy for a period of 6 months or more were administered both curcumin (as Curcuforte) and Ribraxx. Methods. Ten MGUS\/SMM patients and 10 patients with stage 0\/1 CLL were administered 6 g of curcumin and 2 g Ribraxx daily. Blood samples were collected at baseline and at 2-month intervals for a period of 6 months, and various markers were monitored. MGUS\/SMM patients included full blood count (FBC); paraprotein; free light chains\/ratio; C-reactive protein (CRP)and erythrocyte sedimentation rate (ESR); B2 microglobulin and immunological markers. Markers monitored for stage 0\/1 CLL were FBC, CRP and ESR, and immunological markers. Results. Of 10 MGUS\/SMM patients,5 (50%) were neutropenic at baseline, and the Curcuforte\/Ribraxx combination therapy showed an increased neutrophil count, varying between 10% and 90% among 8 of the 10 (80%) MGUS\/SMM patients. An additional benefit of the combination therapy was the potent effect in reducing the raised ESR in 4 (44%) of the MGUS\/SMM patients. Conclusion. Addition of Ribraxx to curcumin therapy may be of benefit to patients with early-stage B-cell lymphoid malignancies.<\/jats:p>","DOI":"10.1177\/1534735416635742","type":"journal-article","created":{"date-parts":[[2016,5,7]],"date-time":"2016-05-07T04:21:49Z","timestamp":1462594909000},"page":"183-189","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":19,"title":["Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0\/1 Chronic Lymphocytic Leukemia)"],"prefix":"10.1177","volume":"15","author":[{"given":"Terry","family":"Golombick","sequence":"first","affiliation":[{"name":"St George Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terrence H.","family":"Diamond","sequence":"additional","affiliation":[{"name":"St George Hospital, Sydney, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arumugam","family":"Manoharan","sequence":"additional","affiliation":[{"name":"University of Wollongong, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajeev","family":"Ramakrishna","sequence":"additional","affiliation":[{"name":"University of Wollongong, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2016,5,6]]},"reference":[{"key":"bibr1-1534735416635742","first-page":"161","volume":"2","author":"Golombick T","year":"2008","journal-title":"Biologics"},{"key":"bibr2-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2217"},{"key":"bibr3-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23159"},{"key":"bibr4-1534735416635742","doi-asserted-by":"publisher","DOI":"10.5430\/jhm.v3n1p18"},{"issue":"2015","key":"bibr5-1534735416635742","first-page":"910528","author":"Golombick T","year":"2015","journal-title":"Case Rep Hematol"},{"key":"bibr6-1534735416635742","doi-asserted-by":"publisher","DOI":"10.4236\/jct.2015.67061"},{"key":"bibr7-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1011442"},{"key":"bibr8-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0108326"},{"key":"bibr9-1534735416635742","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF02914369","volume":"10","author":"Winkelstein A","year":"1992","journal-title":"Clin Rev Allergy"},{"key":"bibr10-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1211\/0022357044922"},{"key":"bibr11-1534735416635742","first-page":"89","volume":"14","author":"Ghoneum M.","year":"1998","journal-title":"Int J Immunother"},{"key":"bibr12-1534735416635742","first-page":"5145","volume":"30","author":"Bang MH","year":"2010","journal-title":"Anticancer Res"},{"key":"bibr13-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdp.2008.02.006"},{"key":"bibr14-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(03)00458-0"},{"key":"bibr15-1534735416635742","first-page":"4187","volume":"25","author":"Ghoneum M","year":"2005","journal-title":"Anticancer Res"},{"key":"bibr16-1534735416635742","first-page":"81","volume":"34","author":"Ghoneum M","year":"2014","journal-title":"Anticancer Res"},{"key":"bibr17-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1177\/039463200401700308"},{"key":"bibr18-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1177\/039463200802100110"},{"key":"bibr19-1534735416635742","first-page":"314","volume":"24","author":"Ghoneum M","year":"2000","journal-title":"Cancer Detect Prev"},{"key":"bibr20-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-012-1344-z"},{"key":"bibr21-1534735416635742","doi-asserted-by":"publisher","DOI":"10.4149\/neo_2011_02_118"},{"key":"bibr22-1534735416635742","volume-title":"Hematology in Clinical Practice","author":"Hillman RS","year":"2005","edition":"4"},{"key":"bibr23-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1080\/00365517909108829"},{"key":"bibr24-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2257.2003.00492.x"},{"key":"bibr25-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2008.01.008"},{"key":"bibr26-1534735416635742","first-page":"349","volume":"2005","author":"Aggarwal BB","journal-title":"Phytopharm Cancer Chemoprev"},{"key":"bibr27-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1158\/1940-6207.CAPR-11-0308"},{"key":"bibr28-1534735416635742","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.11"},{"key":"bibr29-1534735416635742","first-page":"523","volume":"4","author":"Ghoneum M","year":"2015","journal-title":"Int J Immunopathol Pharmacol"}],"container-title":["Integrative Cancer Therapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735416635742","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1534735416635742","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1534735416635742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:18:18Z","timestamp":1777454298000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1534735416635742"}},"subtitle":["A Preliminary Clinical Study"],"short-title":[],"issued":{"date-parts":[[2016,5,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["10.1177\/1534735416635742"],"URL":"https:\/\/doi.org\/10.1177\/1534735416635742","relation":{},"ISSN":["1534-7354","1552-695X"],"issn-type":[{"value":"1534-7354","type":"print"},{"value":"1552-695X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,6]]}}}